News coverage about Boston Scientific (NYSE:BSX) has trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Boston Scientific earned a news impact score of 0.17 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.4750765632531 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
- Boston Scientific (BSX) Earns Buy Rating from Analysts at Canaccord Genuity (americanbankingnews.com)
- Boston Scientific Corporation (NYSE:BSX) Announces Acquisition of Securus Medical Group, Inc (celebcafe.org)
- Boston Scientific (BSX) Price Target Increased to $34.00 by Analysts at Bank of America (americanbankingnews.com)
- Boston Scientific boosts cardiac rhythm unit with $50M takeover (fiercebiotech.com)
- 9 things to know about Boston Scientific (beckersasc.com)
Shares of Boston Scientific stock opened at $28.09 on Friday. The company has a current ratio of 0.68, a quick ratio of 0.49 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $38,140.03, a P/E ratio of 22.02, a P/E/G ratio of 2.01 and a beta of 0.81. Boston Scientific has a one year low of $24.29 and a one year high of $29.93.
A number of research firms have recently issued reports on BSX. Bank of America raised their price target on Boston Scientific from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday. ValuEngine downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday. Barclays restated a “buy” rating and issued a $32.00 price target on shares of Boston Scientific in a research note on Wednesday, January 10th. TheStreet upgraded Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 18th. Finally, Jefferies Group restated a “neutral” rating on shares of Boston Scientific in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $31.45.
In other Boston Scientific news, EVP Kevin J. Ballinger sold 42,803 shares of the firm’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $28.32, for a total transaction of $1,212,180.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Maulik Nanavaty sold 15,568 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $25.38, for a total value of $395,115.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 252,818 shares of company stock worth $6,879,888. Insiders own 0.74% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Boston Scientific (BSX) Given Daily Coverage Optimism Score of 0.17” was reported by BBNS and is owned by of BBNS. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://baseballnewssource.com/2018/04/06/boston-scientific-bsx-given-daily-news-impact-rating-of-0-17/2031066.html.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.